DRC: MSF travels the extra mile to treat sleeping sickness

Travelling by jeep and motorbike, an MSF mobile medical team is making its way through a remote and insecure region of Democratic Republic of Congo to screen and treat people suffering from sleeping sickness.

In a small, dark clinic in the northeastern region of Democratic Republic of Congo (DRC), 24-year-old Germaine lies on a cot, unable to walk because she is so dizzy. She was bitten by a tsetse fly and MSF doctors have diagnosed her with sleeping sickness. 

Germaine is one of 42,000 people MSF is aiming to test and treat for the tropical disease over an eight-month period. In May 2015, mobile medical teams, made up of doctors, nurses and lab technicians, began travelling through dense and unstable regions of Province Orientale, Ango and Banda Territory, near the border with Central African Republic, visiting villages where disease rates have been historically high.

Reaching nomads and refugees

“We are making a big effort to reach people who live beyond the villages,” said Rolland Kaya, MSF’s head of mission for sleeping sickness. “We are focusing on the most vulnerable and hard- to-reach groups of people, such as refugees and nomads living in the bush. A team of public health sensitisers travels to remote farming and fishing communities to let them know we are in the area. We’re encouraging these people to come and get tested because they are most at risk of being bitten and infected by the flies.”

Since May, MSF has screened 12,183 people, 91 of whom have so far been diagnosed with sleeping sickness.

With the team working in such remote areas, MSF is also taking the opportunity to provide people with general healthcare, particularly pregnant women, children under five and adults with malaria symptoms. Since May, the team has treated 6,884 people for malaria.

Too dizzy to work

Early symptoms of sleeping sickness include fever, headaches, joint pain and itching. The drugs used to treat people in the early stages of the disease are relatively easy to administer and non-toxic. The earlier the disease is identified, the better chance there is of a cure. 

In the second stage, parasites cross the blood-brain barrier and infect the central nervous system. This is when more obvious signs of the disease appear, including a disturbed sleep cycle, which gives sleeping sickness its name.

Germaine began showing symptoms of sleeping sickness three months ago, after the birth of her third child. Suffering from fatigue and vertigo, she wasn’t able to go to the fields to work. “I was so dizzy I would fall to the ground,” she recalls. “I had no energy, I couldn’t eat and I could only take sips of water.”

Germaine will spend seven days in the clinic to receive injections of the drug pentamadine. “My family couldn’t understand what was wrong with me,” says Germaine. “They are so relieved that I’m getting treatment and am already starting to feel better.”

Sleeping sickness on decrease

Sleeping sickness continues to affect millions of people in 36 countries in sub-Saharan Africa. Most live in remote, rural areas with limited access to health services. Many have been displaced from their homes by war and poverty. These factors all make it difficult to carry out surveillance, and to diagnose and treat cases.

However, in the past decade, the number of sleeping sickness cases around the world has dropped, and treatments have improved.

MSF has been actively engaged in treating sleeping sickness for 25 years in DRC, Central African Republic, Republic of Congo and South Sudan. MSF teams say they have noticed people in DRC becoming more aware of the dangers of the disease, while behavioural changes, linked to insecurity, are also contributing to the fall in cases.

“We believe the decrease in the number of cases we are seeing is linked to people beginning to change their lifestyles due to the insecurity in the area,” says MSF health advisor Dr Turid Piening. “They are abandoning their traditions of hunting and fishing near rivers where tsetse flies gather, and are cultivating crops closer to home.”

But to eliminate the disease, much more remains to be done, including the development of an easy-to-use rapid test to replace complicated diagnostic procedures, coupled with oral drugs that can be taken at home. Until that happens, MSF is committed to finding, testing and treating people suffering from this life-threatening disease, however remote the area in which they live.